Pharmacokinetics of Weekly Paclitaxel and Feasibility of Dexamethasone Taper in Japanese Patients with Advanced Non-small Cell Lung Cancer.

[1]  C. Shapiro,et al.  Feasibility of stopping paclitaxel premedication after two doses in patients not experiencing a previous infusion hypersensitivity reaction , 2011, Supportive Care in Cancer.

[2]  T. Jobo,et al.  Dose-dense paclitaxel once a week in combination with carboplatin every 3 weeks for advanced ovarian cancer: a phase 3, open-label, randomised controlled trial , 2009, The Lancet.

[3]  H. Kunikane,et al.  Dose-escalating and pharmacokinetic study of a weekly combination of paclitaxel and carboplatin for inoperable non-small cell lung cancer: JCOG 9910-DI. , 2009, Japanese journal of clinical oncology.

[4]  V. Catalano,et al.  Weekly paclitaxel in elderly patients (aged > or = 70 years) with advanced non-small-cell lung cancer: an alternative choice? Results of a phase II study. , 2008, Clinical lung cancer.

[5]  E. Perez,et al.  Weekly paclitaxel in the adjuvant treatment of breast cancer. , 2008, The New England journal of medicine.

[6]  Lyndsay Harris,et al.  Randomized phase III trial of weekly compared with every-3-weeks paclitaxel for metastatic breast cancer, with trastuzumab for all HER-2 overexpressors and random assignment to trastuzumab or not in HER-2 nonoverexpressors: final results of Cancer and Leukemia Group B protocol 9840. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[7]  S. Ramalingam,et al.  Randomized, phase III study of weekly paclitaxel in combination with carboplatin versus standard every-3-weeks administration of carboplatin and paclitaxel for patients with previously untreated advanced non-small-cell lung cancer. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[8]  T. Nukiwa,et al.  A phase II study of weekly paclitaxel combined with carboplatin for elderly patients with advanced non-small cell lung cancer. , 2006, Lung cancer.

[9]  Michael Schroeder,et al.  Multicenter randomized trial for stage IIIB/IV non-small-cell lung cancer using every-3-week versus weekly paclitaxel/carboplatin. , 2006, Clinical lung cancer.

[10]  M. Socinski,et al.  Randomized phase III trial comparing cisplatin-etoposide to carboplatin-paclitaxel in advanced or metastatic non-small cell lung cancer. , 2005, Annals of oncology : official journal of the European Society for Medical Oncology.

[11]  A. Jillella,et al.  A phase II study of weekly paclitaxel and carboplatin in previously untreated patients with advanced non-small-cell lung cancer , 2005, Medical oncology.

[12]  A. Braverman,et al.  Tapering and Discontinuation of Glucocorticoid Prophylaxis during Prolonged Weekly to Biweekly Paclitaxel Administration , 2005, Chemotherapy.

[13]  T. Mukohara,et al.  Phase I/II study of cisplatin combined with weekly paclitaxel in patients with advanced non-small-cell lung cancer , 2004, British Journal of Cancer.

[14]  G. Giaccone,et al.  Three-arm randomized study of two cisplatin-based regimens and paclitaxel plus gemcitabine in advanced non-small-cell lung cancer: a phase III trial of the European Organization for Research and Treatment of Cancer Lung Cancer Group--EORTC 08975. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[15]  M. Ratain,et al.  Weekly, high‐dose paclitaxel in advanced lung carcinoma , 2003, Cancer.

[16]  J. Kwon,et al.  A comparison of two prophylactic regimens for hypersensitivity reactions to paclitaxel. , 2002, Gynecologic oncology.

[17]  David Harrington,et al.  Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer. , 2002, The New England journal of medicine.

[18]  D. Gandara,et al.  Premedication Strategy for Weekly Paclitaxel , 2002, Cancer investigation.

[19]  I. Hyodo,et al.  Phase II trial of paclitaxel by three-hour infusion for advanced gastric cancer with short premedication for prophylaxis against paclitaxel-associated hypersensitivity reactions. , 2001, Annals of oncology : official journal of the European Society for Medical Oncology.

[20]  J. Crowley,et al.  Randomized phase III trial of paclitaxel plus carboplatin versus vinorelbine plus cisplatin in the treatment of patients with advanced non--small-cell lung cancer: a Southwest Oncology Group trial. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[21]  R. Weide,et al.  Dose Reduction of Steroid Premedication for Paclitaxel: No Increase of Hypersensitivity Reactions , 2001, Oncology Research and Treatment.

[22]  M. Jiroutek,et al.  Comparison of survival and quality of life in advanced non-small-cell lung cancer patients treated with two dose levels of paclitaxel combined with cisplatin versus etoposide with cisplatin: results of an Eastern Cooperative Oncology Group trial. , 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[23]  C. Hudis,et al.  Dose-dense therapy with weekly 1-hour paclitaxel infusions in the treatment of metastatic breast cancer. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[24]  S. Wrighton,et al.  Induction of cytochrome P4503A by taxol in primary cultures of human hepatocytes. , 1998, Archives of biochemistry and biophysics.

[25]  R. Dillman,et al.  Single-dose dexamethasone paclitaxel premedication. , 1998, Gynecologic oncology.

[26]  R. Ozols,et al.  Short-course intravenous prophylaxis for paclitaxel-related hypersensitivity reactions. , 1997, Annals of oncology : official journal of the European Society for Medical Oncology.

[27]  N. Saijo,et al.  Phase II study of 3-hour infusion of paclitaxel in previously untreated non-small cell lung cancer. , 1996, Clinical cancer research : an official journal of the American Association for Cancer Research.

[28]  A. Maksymiuk,et al.  Paclitaxel premedication regimens. , 1996, Journal of the National Cancer Institute.

[29]  N. Saijo,et al.  Phase I Study of Paclitaxel by Three‐hour Infusion: Hypotension Just after Infusion Is One of the Major Dose‐limiting Toxicities , 1995, Japanese journal of cancer research : Gann.

[30]  H. Nakanomyo,et al.  [Determination of new anticancer drug, paclitaxel, in biological fluids by high performance liquid chromatography]. , 1994, Yakugaku zasshi : Journal of the Pharmaceutical Society of Japan.

[31]  B. Uziely,et al.  Low doses of dexamethasone protect against paclitaxel (Taxol)-related hypersensitivity reactions following cycle 1. , 1994, Annals of oncology : official journal of the European Society for Medical Oncology.

[32]  N. Tsavaris,et al.  A simplified premedication schedule for 1-hour paclitaxel administration. , 2005, The journal of supportive oncology.